{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-020405","form_type":"8-K/A","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.912377+00:00","generated_at":"2026-05-25T12:40:16.896168+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"confidence":"high","headline":"Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors","bullets":["CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.","Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.","Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.","All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-020405","json":"https://secwatch.observer/filing/0001104659-25-020405.json","markdown":"https://secwatch.observer/filing/0001104659-25-020405.md","text":"https://secwatch.observer/filing/0001104659-25-020405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/0001104659-25-020405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/tm258250d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T12:40:16.896168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}